+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2017-12-07Number of Pages: 237

Erythropoietin Drugs Market (Drug Class - Epoetin Alfa, Epoetin Beta, and Darbepoetin Alfa; Drug Type - Biologics and Biosimilar; Drug Application - Cancer, Renal Disease, Hematology, Neurology, and Others (Surgery and Wound Healing); Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2017 - 2025

Global Erythropoietin Drugs Market: Overview

Erythropoietin drugs can be defined as naturally occurring hormone secreted from the kidney, and perform function in development of red blood cells (RBC) by stimulating the bone marrow tissues in the bone. Rising the RBC count increases the hemoglobin level in the blood stream, transport the sufficient amount of oxygen in every part of body. The market is anticipated to grow at a significant rate owing to various factors such as high return on investments, patent expiration of erythropoietin drugs, and growing focus on awareness programs by the governmental and non-governmental organizations, and tax credits and fee waivers offered by the government, among others. According to the research report, the global erythropoietin drugs market is expected to be worth US$19,379.2 mn by the end of 2025, as the market rises at a steady CAGR of 7.5% between 2017 and 2025.

erythropoietin drugs market

Cancer to Remain Critical to Escalating Demand for Erythropoietin Drugs over Forecast Period

On the basis of drug class, the market has been segmented into epoetin alfa, epoetin beta, darbepoetin alfa, others. Epoetin alfa was the dominant segment in 2016. It is anticipated to remain dominant in the forecast period, in terms of revenues. Epoetin alfa is usually related with cancer chemotherapy and chronic renal failure. Rising the prevalence of cancer worldwide according to National institute of cancer, 1,685,210 new cases of cancer estimated in year 2016. On the basis of drug application, the market has been segmented into cancer, renal disease, hematology, neurology, others (surgery, wound healing, etc.). Cancer was the dominant segment in 2016. It is anticipated to remain dominant in the forecast period, in terms of revenues, owing to the factors such as increasing prevalence of chronic diseases globally.

Based on drug type, the market has been segmented into biologics and biosimilars. The biologic erythropoietin drugs dominated the market in 2016 and are anticipated to remain dominant in the forecast period. This segment is anticipated to grow at a high CAGR during the forecast period owing to long drug exclusivity period, which provides manufacturers a high return on investment (ROI). On the basis of distribution channel, the market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2016 and is anticipated to remain the dominant segment in terms of revenues in the forecast period. The online pharmacy segment is anticipated to grow at a significant high CAGR during the forecast period, owing to the factors such as increasing reach of online pharmacy to the customers, rising the internet facilities globally, and other services such as cost containment offered by online pharmacy. 

Higher Approval Rate of Erythropoietin Drugs in North America Boosts Growth of Regional Market

Geographically, the market has been segmented into five regions, including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. North America was the dominant region in terms of revenues in 2016 and is anticipated to remain dominant in the forecast period. The growth in the region can be attributed to the increasing approvals of erythropoietin drugs, government incentives offered for research on chronic disease such as research and development grants, drug exclusivity, tax credit and fee waivers, among others.

Europe is anticipated to be the trailing next in terms of revenues in the forecast period. This growth can be attributed to the increasing prevalence of chronic diseases in the region. Growth of the segment is led by government initiatives for cancer and other chronic disease treatment. Governments of various countries in the region are taking efforts to decrease the rate of incidence of cancer. Asia Pacific region is growing with highest CAGR value. High incidence rate of hematological diseases in countries such as India, China, Bangladesh, and Pakistan is driving the erythropoietin drugs market in Asia Pacific.

Major players in the erythropoietin drugs market include Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson, Wockhardt Ltd., Pfizer, Inc., Biocon Ltd., Teva Pharmaceutical Industries Ltd. etc., among others.

Global Erythropoietin Drugs Market: Snapshot

Erythropoietin is a hormone which produce inside the body from kidney. EPO helps in the development of RBC inside the body and high number of RBC increases the level of hemoglobin in the blood which transport the oxygen in every part of the body. The market for these erythropoietin drugs is anticipated to grow significantly in the forecast period, owing to the rising prevalence of chronic diseases, focus of government and non-government organizations on creating awareness, research and development grants, and fee waivers and tax credits offered, among others.  

Global Erythropoietin Drugs Market: Research Methodologies

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of drugs employed in the treatment of chronic diseases in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market size in terms of US$ Mn for drug class, drug type, drug application, distribution channel, and geography for the period 2015 to 2025, considering the macro and micro environmental factors. The revenue generated from each drug class, drug type, drug application, and distribution channel was calculated by considering the prevalence of chronic diseases, erythropoietin drug approvals, regulatory procedures, and the awareness of chronic diseases across all the geographies.

Global Erythropoietin Drugs Market: Segmentation

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on drug class, drug type, drug application, distribution channel, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the erythropoietin drugs market in the current and future scenario. The report also provides Porter’s five forces analysis, the acquisitions timeline of erythropoietin drug companies, SWOT analysis of the market, regulatory scenario, comparative analysis of erythropoietin drug policies, chronic diseases prevalence, pricing scenario of the erythropoietin drugs, major selling erythropoietin drugs, and drug exclusivity of certain of the erythropoietin drugs,  for the market.

Global Erythropoietin Drugs Market: Competitive Landscape

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The study also covers detailed country analysis contributing majorly in the erythropoietin drugs market.

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Companies profiled in the erythropoietin drugs market report are Amgen Inc., Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson, Wockhardt Ltd., Pfizer, Inc., Biocon Ltd., and Teva Pharmaceutical Industries Ltd. among others.

The Erythropoietin Drugs Market has been segmented as follows:

  • Erythropoietin Drugs Market, by Drug Class, Revenue (US$ Mn) 2015-2025
    • Epoetin Alfa
    • Epoetin Beta
    • Darbepoetin Alfa
    • Others
       
  • Erythropoietin Drugs Market, by Drug Type, Revenue (US$ Mn) 2015-2025
    • Biologics
    • Biosimilar
       
  • Erythropoietin Drugs Market, by Drug Application, Revenue (US$ Mn) 2015-2025
    • Cancer
    • Renal Disease
    • Hematology
    • Neurology
    • Others (Surgery, Wound healing, etc.)
       
  • Erythropoietin Drugs Market, by Drug Application, Revenue (US$ Mn) 2015-2025
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
       
  • Erythropoietin Drugs Market Revenue, by Geography (US$ Mn), 2015-2025
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • Spain
      • France
      • Italy
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of LATAM
    • Middle East and Africa
      • GCC Countries
      • Israel
      • South Africa
      • Rest of MEA


 
 
Back To Top